Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Adva...
October 23 2015 - 8:15AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that it would provide a meaningful update on its CD20
Chimeric Antigen Receptor T-cell (CAR-T) Phase IIa trial in
Advanced, Refractory or Relapsed Diffuse Large B-Cell Lymphoma
(DLBCL) at the upcoming 4th International Conference on
Translational Medicine to be held on October 26-28, 2015 in
Baltimore, Maryland, USA.
Title: Treatment of CD20-directed chimeric
antigen receptor-modified T cells in patients with relapsed or
refractory B-cell Non-Hodgkin’s lymphoma: An early Phase IIa trial
reportScientific Program: October 26, 2015
16:15-16:40 EDT Location: DoubleTree by
Hilton Hotel Baltimore - BWI Airport, Chesapeake Hall
Presenter: Yihong Yao, Ph.D., Chief
Scientific Officer, Cellular Biomedicine Group
Full details of the presented data will be
available on the Company’s website following the presentation.
About Cellular Biomedicine
Group
Cellular Biomedicine Group, Inc. develops
proprietary cell therapies for the treatment of certain
degenerative and cancerous diseases. Our developmental stem cell
and Immuno-Oncology projects are the result of research and
development by scientists and doctors
from China and the United States. Our GMP facilities
in China, consisting of nine independent cell production lines, are
designed, certified and managed according to U.S. standards. To
learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024